Skip to content
Screener

Treasury Stock at other companies

Pfizer logo
PfizerPFE
$115.19B+0.2%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$270.5M+15.3%
Viatris logo
ViatrisVTRS
$1.16B+35.2%
Opko Health logo
Opko HealthOPK
$2.36M+31.9%
AptarGroup logo
AptarGroupATR
$1.05B+55.6%
Abbott logo
AbbottABT
$17.97B+8.2%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$916.25M-28.0%
Enterprise value$1.38B-20.6%
P/E11.7×+2.2×
P/S1.3×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemJune 30, 2026December 31, 2025
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 62,306,254 and 42,532,225 shares issued and outstanding, respectively, as of June 30, 2026 and 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 202566
Additional paid-in capital553,002535,380
Retained earnings703,649666,881
Accumulated other comprehensive loss(5,904)(5,314)
Treasury stock(482,596)(408,148)
Total stockholders' equity768,157788,805
Total liabilities and stockholders’ equity$1,743,766$1,629,299

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's treasury stock?
Amphastar Pharmaceuticals (AMPH) reported treasury stock of $482.6M in Q2 2026.
How has Amphastar Pharmaceuticals's treasury stock changed year-over-year?
Amphastar Pharmaceuticals's treasury stock increased by 26.1% year-over-year, from $382.85M to $482.6M.
What is the long-term trend for Amphastar Pharmaceuticals's treasury stock?
Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's treasury stock has grown at a 27.4% compound annual growth rate (CAGR), from $121.81M to $408.15M.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Ask your AI about Amphastar Pharmaceuticals's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude